Deinove infectious, agbio/environmental news

Deinove established its Deinobiotics S.A.S. subsidiary to develop antibodies derived from the Deinococci bacteria. Deinove, which owns 49% of Deinobiotics, granted the subsidiary rights to Deinove's IP related to antibiotics research. The Holding Incubator Green Chemistry invested €0.5 million ($0.7 million) in Deinobiotics and is the majority shareholder with a 51% stake. Deinove has the option to buy back all Deinobiotics shares sold to the holding company. Deinove uses the fermentation and metabolic capabilities of the Deinococci bacteria to produce second-generation biofuels and chemical intermediates. ...